Home >

Baiyun Mountain A:1-9 Monthly Performance Increased By 130-180%&Nbsp; Highly Recommended.

2010/9/14 16:44:00 87

Main points

First, participate in anti "

Super bacteria

"Drug research and development, good long-term development.

In September 11, 2010, Guangyao group launched the research and development project on anti superbug drugs. The company confirmed that 10 major anti-inflammatory and anti-inflammatory Chinese medicines involved in the improvement of drug resistance research may involve products such as Qingkailing series, nantizhi Xiaoyan capsule, Banlangen Granule, Kou Yanqing granule, etc., to study the antimicrobial resistance of the above antibacterial and anti-inflammatory traditional Chinese medicines, so as to provide reference and help for the selection of medicines for doctors and patients. At the same time, we should carry out research on new anti-inflammatory and anti-inflammatory drugs, accelerate the pformation of scientific and technological achievements, and promote the long-term development of the company.

Two.

Sales situation

Chang Wang, 130%-180% increased by 1-9 in the month.

The company's marketing reform has shown the effect, benefiting from the promotion of medical reform and the expansion of the medical market. The sales situation of leading products has been flourishing, and its performance has increased significantly. The EPS 0.2646 yuan has achieved the best level in the past 5 years.

The company expects to achieve a net profit of 15326-18658 yuan in 1-9 months in 2010, an increase of 130%-180% over the previous year, corresponding to EPS 0.3268-0.3979 yuan.

Three, Guangyao group is more likely to merge its internal resources for overall listing.

This year Guangyao group put forward the "12th Five-Year plan". The goal is to increase business income from the current 27 billion yuan to 60 billion yuan in 2015.

We believe that if the Guangyao group only strengthens its R & D and market development efforts or relies solely on endogenous development, it will be difficult to increase sales revenue by more than 1 times in 5 years.

Although the two listed companies have focused on the pharmaceutical industry, the main R & D direction and industry are the same. In the face of the integration and strategic expansion of the Chinese medicine, Huarun, and the strategic expansion, the Guangyao group will face strategic choices. The pharmaceutical industry is going to integrate the resources of the pharmaceutical industry and increase the synergy and competitiveness.

Four, investment advice: strongly recommended (maintenance).

We maintain our company's performance forecast for 2010-2012 years EPS 0.51, 0.66 and 0.84 yuan, corresponding to PE 33X, 25X and 20X respectively.

We believe that the company has entered the fast track.

Development period

The company will continue to benefit from the expansion of the primary health care market. The company has 1300 mu of high-quality land, and there is the expected integration of Guangyao group. It will take part in the research and development of anti superbug drugs, study the improvement of drug resistance and antiseptic and anti-inflammatory new drugs of Chinese Medicine for long-term development, maintain the "highly recommended" rating, the target price of 6 months is 19.8 yuan, and the target price of 12 months is 29.8 yuan.